Towards targeted delivery systems: Ligand conjugation strategies for mRNA nanoparticle tumor vaccines

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Phua, Kyle K L ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CLEC9A RECEPTOR; DEC 205 RECEPTOR; LIGAND; MANNOSE RECEPTOR; MESSENGER RNA; NANOPARTICLE; POLYGLACTIN; RECEPTOR; TUMOR VACCINE; UBIQUITIN; UNCLASSIFIED DRUG; CANCER VACCINE; MEMBRANE PROTEIN;

ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; DENDRITIC CELL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; ENDOSOME; GENE TARGETING; GENETIC IMMUNIZATION; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; NANOENCAPSULATION; NONHUMAN; PHYSIOLOGICAL PROCESS; POLYMERIZATION; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CHEMISTRY; GENE TRANSFER; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHYSIOLOGY; TRANSPLANTATION; VACCINATION;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; HUMANS; LIGANDS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASMS; RNA, MESSENGER; VACCINATION;

EID: 84954504764     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/680620     Document Type: Review

References (88)

1. S. Zou, K. Scarfo, M. H. Nantz, and J. G. Hecker, "Lipidmediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells, " International Journal of Pharmaceutics, vol. 389, no. 1-2, pp. 232-243, 2010.
2. M. L. Read, S. Singh, Z. Ahmed et al. , "A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids, " Nucleic Acids Research, vol. 33, no. 9, 2005.
3. K. K. L. Phua, K. W. Leong, and S. K. Nair, "Transfection efficiency and transgene expression kinetics ofmRNA delivered in naked and nanoparticle format, " Journal ofControlled Release, vol. 166, no. 3, pp. 227-233, 2013.
4. J. Probst, B. Weide, B. Scheel et al. , "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent, " GeneTherapy, vol. 14, no. 15, pp. 1175-1180, 2007.
5. D. M. Ashley, B. Faiola, S. Nair, L. P. Hale, D. D. Bigner, and E. Gilboa, "Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous systemtumors, " Journal of Experimental Medicine, vol. 186, no. 7, pp. 1177-1182, 1997.
6. F. T. Zohra, E. H. Chowdhury, S. Tada, T. Hoshiba, and T. Akaike, "Effective delivery with enhanced translational activity synergistically acceleratesmRNA-based transfection, " Biochemical and Biophysical Research Communications, vol. 358, no. 1, pp. 373-378, 2007.
7. A. N. Kuhn, M. Diken, S. Kreiter et al. , "Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo, " GeneTherapy, vol. 17, no. 8, pp. 961-971, 2010.
8. S. Kreiter, A. Selmi, M. Diken et al. , "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity, " Cancer Research, vol. 70, no. 22, pp. 9031-9040, 2010.
9. K. K. L. Phua, H. F. Staats, K. W. Leong, and S. K. Nair, "Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity, " Scientific Reports, vol. 4, article 5128, 2014.
10. L. A. Brito, M. Chan, C. A. Shawet al. , "Acationicnanoemulsion for the delivery of next-generation RNA vaccines, " Molecular Therapy, vol. 22, no. 12, pp. 2118-2129, 2014.
11. X. F. Su, J. Fricke, D. G. Kavanagh, and D. J. Irvine, "In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles, " Molecular Pharmaceutics, vol. 8, no. 3, pp. 774-787, 2011.
12. F. T. Zohra, E. H. Chowdhury, M. Nagaoka, and T. Akaike, "Drastic effect of nanoapatite particles on liposome-mediated mRNA delivery to mammalian cells, " Analytical Biochemistry, vol. 345, no. 1, pp. 164-166, 2005.
13. H. Debus, P. Baumhof, J. Probst, and T. Kissel, "Delivery of messenger RNA using poly(ethylene imine)-poly(ethylene glycol)-copolymer blends for polyplex formation: biophysical characterization and in vitro transfection properties, " Journal of Controlled Release, vol. 148, no. 3, pp. 334-343, 2010.
14. C. Goncalves, M. Berchel, M.-P. Gosselin et al. , "Lipopolyplexes comprising imidazole/imidazolium lipophosphoramidate, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection, " International Journal of Pharmaceutics, vol. 460, no. 1-2, pp. 264-272, 2014.
15. A. J. Geall, A. Verma, G. R. Otten et al. , "Nonviral delivery of self-amplifying RNA vaccines, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 36, pp. 14604-14609, 2012.
16. Y.-L. Chiu, H. F. Chan, K. K. L. Phua et al. , "Synthesis of fluorosurfactants for emulsion-based biological applications, " ACS Nano, vol. 8, no. 4, pp. 3913-3920, 2014.
17. A. Basarkar, D. Devineni, R. Palaniappan, and J. Singh, "Preparation, characterization, cytotoxicity and transfection efficiency of poly(dl-lactide-co-glycolide) and poly(dl-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA, " International Journal of Pharmaceutics, vol. 343, no. 1-2, pp. 247-254, 2007.
18. E. Cohen-Sela, S. Teitlboim, M. Chorny et al. , "Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity, " Journal of Pharmaceutical Sciences, vol. 98, no. 4, pp. 1452-1462, 2009.
19. J. Cheng, B. A. Teply, I. Sherifi et al. , "Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery, " Biomaterials, vol. 28, no. 5, pp. 869-876, 2007.
20. A. N. Glazer, "Bioconjugate techniques-Hermanson, GT, " Nature, vol. 381, no. 6580, p. 290, 1996.
21. W. Poon, X. Zhang, D. Bekah, J. G. Teodoro, and J. L. Nadeau, "Targeting B16 tumors in vivo with peptide-conjugated gold nanoparticles, " Nanotechnology, vol. 26, no. 28, Article ID 285101, 2015.
22. J. Park, T. Mattessich, S. M. Jay, A. Agawu, W. M. Saltzman, and T. M. Fahmy, "Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates, " Journal of Controlled Release, vol. 156, no. 1, pp. 109-115, 2011.
23. V. Krishnan, X. Xu, D. Kelly et al. , "CD19-Targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia, " Molecular Pharmaceutics, vol. 12, no. 6, pp. 2101-2111, 2015.
24. L. J. Cruz, P. J. Tacken, R. Fokkink, and C. G. Figdor, "The influence of PEG chain length and targeting moiety on antibodymediated delivery of nanoparticle vaccines to human dendritic cells, " Biomaterials, vol. 32, no. 28, pp. 6791-6803, 2011.
25. R. van der Meel, L. J. C. Vehmeijer, R. J. Kok, G. Storm, and E. V. B. van Gaal, "Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status, " Advanced Drug Delivery Reviews, vol. 65, no. 10, pp. 1284-1298, 2013.
26. S. Ring, M. Maas, D. M. Nettelbeck, A. H. Enk, and K. Mahnke, "Targeting of autoantigens to DEC205+ dendritic cells in vivo suppresses experimental allergic encephalomyelitis in mice, " Journal of Immunology, vol. 191, no. 6, pp. 2938-2947, 2013.
27. T. S. Johnson, K. Mahnke, V. Storn et al. , "Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule, " Clinical Cancer Research, vol. 14, no. 24, pp. 8169-8177, 2008.
28. Y. H. Lao, K. K. L. Phua, and K. W. Leong, "Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation, " ACS Nano, vol. 9, no. 3, pp. 2235-2254, 2015.
29. S. P. Vyas, A. K. Goyal, and K. Khatri, "Mannosylated liposomes for targeted vaccines delivery, " Methods in Molecular Biology, vol. 605, pp. 177-188, 2010.
30. P. K. Sahu, D. K. Mishra, N. Jain, V. Rajoriya, and A. K. Jain, "Mannosylated solid lipid nanoparticles for lung-targeted delivery of Paclitaxel, " Drug Development and Industrial Pharmacy, vol. 41, no. 4, pp. 640-649, 2015.
31. F. Perche, D. Gosset, M. Mevel et al. , "Selective gene delivery in dendritic cells with mannosylated and histidylated lipopolyplexes, " Journal ofDrug Targeting, vol. 19, no. 5, pp. 315-325, 2011.
32. Y. Peng, W. Yao, B. Wang, and L. Zong, "Mannosylated chitosan nanoparticles based macrophage-targeting gene delivery system enhanced cellular uptake and improved transfection efficiency, " Journal of Nanoscience and Nanotechnology, vol. 15, no. 4, pp. 2619-2627, 2015.
33. I. Y. Park, I. Y. Kim, M. K. Yoo, Y. J. Choi, M.-H. Cho, and C. S. Cho, "Mannosylated polyethylenimine coupled mesoporous silica nanoparticles for receptor-mediated gene delivery, " International Journal of Pharmaceutics, vol. 359, no. 1-2, pp. 280-287, 2008.
34. T. H. Kim, J. W. Nah, M.-H. Cho, T. G. Park, and N. S. Cho, "Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles, " Journal of Nanoscience and Nanotechnology, vol. 6, no. 9-10, pp. 2796-2803, 2006.
35. C. H. Jones, M. Chen, A. Gollakota et al. , "Structure-function assessment of mannosylated poly(β-amino esters) upon targeted antigen presenting cell gene delivery, " Biomacromolecules, vol. 16, no. 5, pp. 1534-1541, 2015.
36. N. Kim, D. Jiang, A. M. Jacobi et al. , "Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA, " International Journal of Pharmaceutics, vol. 427, no. 1, pp. 123-133, 2012.
37. F. Perche, T. Benvegnu, M. Berchel et al. , "Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA, " Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 7, no. 4, pp. 445-453, 2011.
38. M. Rovira-Bru, D. H. Thompson, and I. Szleifer, "Size and structure of spontaneously forming liposomes in lipid/PEGlipid mixtures, " Biophysical Journal, vol. 83, no. 5, pp. 2419-2439, 2002.
39. M. R. Toh and G. N. Chiu, "Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing, " Asian Journal of Pharmaceutical Sciences, vol. 8, no. 2, pp. 88-95, 2013.
40. G. Tresset, "The multiple faces of self-assembled lipidic systems, " PMC Biophysics, vol. 2, no. 1, p. 3, 2009.
41. M. A. Monck, A. Mori, D. Lee et al. , "Stabilized plasmidlipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection, " Journal of DrugTargeting, vol. 7, no. 6, pp. 439-452, 2000.
42. T. M. Allen, P. Sapra, and E. Moase, "Use of the post-insertion method for the formation of ligand-coupled liposomes, " Cellular and Molecular Biology Letters, vol. 7, no. 2, pp. 217-219, 2002.
43. M. Shahin, R. Soudy, H. El-Sikhry, J. M. Seubert, K. Kaur, and A. Lavasanifar, "Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin, " Cancer Letters, vol. 334, no. 2, pp. 284-292, 2013.
44. P. J. Photos, L. Bacakova, B. Discher, F. S. Bates, and D. E. Discher, "Polymer vesicles in vivo: correlations with PEG molecular weight, " Journal of Controlled Release, vol. 90, no. 3, pp. 323-334, 2003.
45. S.-D. Li and L. Huang, "Surface-modified LPD nanoparticles for tumor targeting, " Annals of the New York Academy of Sciences, vol. 1082, pp. 1-8, 2006.
46. K. K. L. Phua, S. K. Nair, and K. W. Leong, "Messenger RNA (mRNA) nanoparticle tumour vaccination, " Nanoscale, vol. 6, no. 14, pp. 7715-7729, 2014.
47. J. Wang, Z. Lu, M. G. Wientjes, and J. L.-S. Au, "Delivery of siRNA therapeutics: barriers and carriers, " The AAPS Journal, vol. 12, no. 4, pp. 492-503, 2010.
48. H. Yin, R. L. Kanasty, A. A. Eltoukhy, A. J. Vegas, J. R. Dorkin, and D. G. Anderson, "Non-viral vectors for gene-based therapy, " Nature Reviews Genetics, vol. 15, no. 8, pp. 541-555, 2014.
49. H. L. Amand, H. A. Rydberg, L. H. Fornander, P. Lincoln, B. Norden, and E. K. Esbjorner, "Cell surface binding and uptake of arginine-and lysine-rich penetratin peptides in absence and presence of proteoglycans, " Biochimica et Biophysica Acta-Biomembranes, vol. 1818, no. 11, pp. 2669-2678, 2012.
50. C. He, Y. Hu, L. Yin, C. Tang, and C. Yin, "Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles, " Biomaterials, vol. 31, no. 13, pp. 3657-3666, 2010.
51. E. Frohlich, "The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles, " International Journal of Nanomedicine, vol. 7, pp. 5577-5591, 2012.
52. J. E. Ziello, Y. Huang, and I. S. Jovin, "Cellular endocytosis and gene delivery, "MolecularMedicine, vol. 16, no. 5-6, pp. 222-229, 2010.
53. D. J. Shedlock and D. B. Weiner, "DNAvaccination: antigen presentation and the induction of immunity, " Journal of Leukocyte Biology, vol. 68, no. 6, pp. 793-806, 2000.
54. J. Rice, C. H. Ottensmeier, and F. K. Stevenson, "DNA vaccines: precision tools for activating effective immunity against cancer, " Nature Reviews Cancer, vol. 8, no. 2, pp. 108-120, 2008.
55. K. K. Tran and H. Shen, "The role of phagosomal pHon the sizedependent efficiency of cross-presentation by dendritic cells, " Biomaterials, vol. 30, no. 7, pp. 1356-1362, 2009.
56. G. S. Asthana, A. Asthana, D. V. Kohli, and S. P. Vyas, "Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting, " BioMed Research International, vol. 2014, Article ID 526391, 17 pages, 2014.
57. L. Cui, J. A. Cohen, K. E. Broaders, T. T. Beaudette, and J. M. J. Frechet, "Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting, " Bioconjugate Chemistry, vol. 22, no. 5, pp. 949-957, 2011.
58. M. J. Joralemon, K. S. Murthy, E. E. Remsen, M. L. Becker, and K. L. Wooley, "Synthesis, characterization, and bioavailability of mannosylated shell cross-linked nanoparticles, " Biomacromolecules, vol. 5, no. 3, pp. 903-913, 2004.
59. K. L. Douglas, C. A. Piccirillo, and M. Tabrizian, "Cell linedependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors, " European Journal of Pharmaceutics and Biopharmaceutics, vol. 68, no. 3, pp. 676-687, 2008.
60. C. G. Figdor, Y. van Kooyk, and G. J. Adema, "C-type lectin receptors on dendritic cells and langerhans cells, " Nature Reviews Immunology, vol. 2, no. 2, pp. 77-84, 2002.
61. P. J. Tacken and C. G. Figdor, "Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines, " Seminars in Immunology, vol. 23, no. 1, pp. 12-20, 2011.
62. K. K. L. Phua, D. Boczkowski, J. Dannull, S. Pruitt, K. W. Leong, and S. K. Nair, "Whole blood cells loaded withmessenger RNA as an anti-tumor vaccine, " Advanced Healthcare Materials, vol. 3, no. 6, pp. 837-842, 2014.
63. R. E. Shrimpton, M. Butler, A.-S. Morel, E. Eren, S. S. Hue, and M. A. Ritter, "CD205 (DEC-205): a recognition receptor for apoptotic and necrotic self, "Molecular Immunology, vol. 46, no. 6, pp. 1229-1239, 2009.
64. M. H. Lahoud, F. Ahmet, J.-G. Zhang et al. , "DEC-205 is a cell surface receptor for CpG oligonucleotides, " Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 40, pp. 16270-16275, 2012.
65. L. Bonifaz, D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig, and R. M. Steinman, "Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance, " Journal of ExperimentalMedicine, vol. 196, no. 12, pp. 1627-1638, 2002.
66. B. C. Wengerter, J. A. Katakowski, J. M. Rosenberg et al. , "Aptamer-targeted antigen delivery, "MolecularTherapy, vol. 22, no. 7, pp. 1375-1387, 2014.
67. S. J. Lee, S. Evers, D. Roeder et al. , "Mannose receptor-mediated regulation of serumglycoprotein homeostasis, " Science, vol. 295, no. 5561, pp. 1898-1901, 2002.
68. C. Leteux, W. Chai, R. W. Loveless et al. , "The cysteine-rich domain of the macrophage mannose receptor is a multispecific lectin that recognizes chondroitin sulfates A and B and sulfated oligosaccharides of blood group Lewis(a) and Lewis(x) types in addition to the sulfated N-glycans of lutropin, " The Journal of Experimental Medicine, vol. 191, no. 7, pp. 1117-1126, 2000.
69. Y. Liu, A. J. Chirino, Z. Misulovin et al. , "Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand, " Journal of ExperimentalMedicine, vol. 191, no. 7, pp. 1105-1115, 2000.
70. L. Martinez-Pomares, D. Wienke, R. Stillion et al. , "Carbohydrate-independent recognition of collagens by the macrophage mannose receptor, " European Journal of Immunology, vol. 36, no. 5, pp. 1074-1082, 2006.
71. G. Hajishengallis, S. Liang, M. Wang, and K. Triantafilou, "Microbial immune evasion through exploitation of macrophage pattern-recognition receptors, " Cytokine, vol. 48, no. 1-2, p. 16, 2009.
72. P. R. Taylor, L. Martinez-Pomares, M. Stacey, H.-H. Lin, G. D. Brown, and S. Gordon, "Macrophage receptors and immune recognition, " Annual Review of Immunology, vol. 23, pp. 901-944, 2005.
73. S. Burgdorf, V. Lukacs-Kornek, and C. Kurts, "The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation, " Journal of Immunology, vol. 176, no. 11, pp. 6770-6776, 2006.
74. A. Ghaemmaghami, F. Shakib, L. Martinez-Pomares, and C. Yang, "The role of Mannose receptor in allergen recognition by human dendritic cells (DC), " Journal of Allergy and Clinical Immunology, vol. 121, no. 2, p. S11, 2008.
75. X. Dong, W. J. Storkus, and R. D. Salter, "Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells, " The Journal of Immunology, vol. 163, no. 10, pp. 5427-5434, 1999.
76. J. Westermann, O. Hopfer, A. Aicher, M. Zenke, B. Dorken, and A. Pezzutto, "Mannose-receptor mediated gene-transfer in human dendritic cells, " Blood, vol. 90, no. 10, pp. 2453-2453, 1997.
77. A. M. Mommaas, A. Tan, J. W. Drijfhout et al. , "Cultured dendritic cells use mannose receptor mediated uptake of antigens for efficient HLA-class II restricted antigen presentation, " Journal of InvestigativeDermatology, vol. 109, no. 3, p. 477, 1997.
78. V. Apostolopoulos, G. A. Pietersz, S. Gordon, L. Martinez-Pomares, and L. F. C. McKenzie, "Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway, " European Journal of Immunology, vol. 30, no. 6, pp. 1714-1723, 2000.
79. F. Sallusto, M. Cella, C. Danieli, and A. Lanzavecchia, "Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products, " Journal of Experimental Medicine, vol. 182, no. 2, pp. 389-400, 1995.
80. V. Ramakrishna, J. F. Treml, L. Vitale et al. , "Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules, " Journal of Immunology, vol. 172, no. 5, pp. 2845-2852, 2004.
81. J.-G. Zhang, P. E. Czabotar, A. N. Policheni et al. , "The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments, " Immunity, vol. 36, no. 4, pp. 646-657, 2012.
82. P. Hanc, T. Fujii, S. Iborra et al. , "Structure of the complex of F-actin and DNGR-1, a C-type lectin receptor involved in dendritic cell cross-presentation of dead cell-associated antigens, " Immunity, vol. 42, no. 5, pp. 839-849, 2015.
83. S. Zelenay, A. M. Keller, P. G. Whitney et al. , "The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice, " The Journal of Clinical Investigation, vol. 122, no. 5, pp. 1615-1627, 2012.
84. E. van der Aa, N. van Montfoort, and A. M. Woltman, "BDCA3+CLEC9A+ human dendritic cell function and development, " Seminars in Cell and Developmental Biology, vol. 41, pp. 39-48, 2015.
85. D. Sancho, D. Mourao-Sa, O. P. Joffre et al. , "Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin, " The Journal of Clinical Investigation, vol. 118, no. 6, pp. 2098-2110, 2008.
86. I. Caminschi, A. I. Proietto, F. Ahmet et al. , "The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement, " Blood, vol. 112, no. 8, pp. 3264-3273, 2008.
87. G. Schreibelt, L. J. J. Klinkenberg, L. J. Cruz et al. , "The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells, " Blood, vol. 119, no. 10, pp. 2284-2292, 2012.
88. J. Idoyaga, A. Lubkin, C. Fiorese et al. , "Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8dendritic cellswithin antibodies to Langerin, DEC205, and Clec9A, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 6, pp. 2384-2389, 2011.